ASU begins clinical study for cancer-preventing vaccineMay 10, 2019An Arizona State University (ASU) professor has begun a five-year clinical study examining the effectiveness of a cancer-preventing vaccine for dogs. Stephen Johnston, PhD, a scientist, professor at the School of Life Sciences, and director of the Biodesign Center for Innovations in Medicine, developed the vaccine over a span of 12 years. He says his goal is to change the way veterinarians treat cancer by preventing it before it can start. Over the course of the five-year study, 800 dogs will either be given the vaccine or a placebo and will be monitored. The University of Wisconsin (UW) School of Veterinary Medicine, Colorado State University (CSU) and University of California (UC), Davis are also participating in the trial. "We're testing a totally novel way of creating an anticancer immune response," says David Vail, DVM, DACVIM (oncology), professor and board-certified oncologist at the UW School of Veterinary Medicine. "The holy grail would be to prevent cancer as opposed to waiting for it to start and then treating it." The vaccine is designed to target common canine cancers, including lymphoma, osteosarcoma, hemangiosarcoma, and mastocytomas. At the beginning, two sets of vaccines will be given every two weeks and then annually. The …
SPONSORED CONTENTSupport patients' cognitive function and mobility.Cognitive and mobility decline are common issues facing aging pets, and new Hill's Prescription Diet Brain Care + j/d can help. + Learn More
Torigen Pharma wins 2018 KC Animal Health Corridor Innovation AwardAugust 30, 2018Torigen Pharmaceuticals Inc., a Farmington, Conn., company that provides personalized cancer immunotherapies to the veterinary market, has won the Innovation Award at the KC Animal Health Corridor Investment Forum in Kansas City, Mo. Torigen presented its autologous immunotherapeutic cancer vaccine, VVax-001, for dogs during the forum. The company was honored with the award and a check for $10,000. Torigen was among 12 emerging animal health companies from three countries who competed for investments in a "Shark Tank" format with more than 400 venture capital funds, investment firms, and potential partners at the 10th annual KC Animal Health Investment Forum on Aug. 21. Each company was given 10 minutes to present their ideas followed by a five-minute Q&A. Presenting companies were seeking anywhere from $500,000 to $20 million in funding and had revenue projections of $20 million within five to seven years. A national committee of agricultural and animal health experts selected the finalists. The Investment Forum in Kansas City is one of the world's only opportunities for early-and mid-stage animal health entrepreneurs to present their business plans and provide an inside look at the newest technology and innovations to potential investors. "The Global Animal Health Investment Forum is the …
ELIAS presents preliminary canine osteosarcoma results at ACVIMAugust 3, 2018During the 2018 American College of Veterinary Internal Medicine Forum in June, ELIAS Animal Health, a clinical stage development company advancing novel treatments for companion animal cancer, shared preliminary canine osteosarcoma results for its cancer immunotherapy. According to study results presented by Brian Flesner, DVM, DACVIM (Oncology), University of Missouri, the company's new ELIAS autologous cancer vaccine, featuring a patented vaccine and T cell infusion combination approach, demonstrated "impressive survival times and minimal side effects." This cancer immunotherapeutic is being distributed as an experimental product under 9 CFR 103.3 to veterinarians treating dogs diagnosed with cancer. Efficacy and safety have not been established. One in four dogs will be impacted by cancer in their lifetimes, and cancer is the No. 1 cause of death in dogs older than 2. "There has been growing frustration in the veterinary profession with current treatment options, including chemotherapy and radiation, which have only modestly improved outcomes over the past 20 years," said Noe Reyes, DVM, medical director, ELIAS Animal Health. "We are very encouraged by the positive treatment outcomes reported by Dr. Flesner at ACVIM and look forward to starting our pivotal osteosarcoma trial evaluating this T cell-based immunotherapy in a broader population," …
